# Exploring the Utility of [18F]3F4AP for Demyelination Imaging

> **NCT06999434** · PHASE1 · RECRUITING · sponsor: **Yale University** · enrollment: 105 (estimated)

## Conditions studied

- Demyelinating Disorders
- MCI
- Alzheimer's Disease (AD)
- MS (Multiple Sclerosis)
- SCI - Spinal Cord Injury
- Spinal Radiculopathy

## Interventions

- **DRUG:** [ 18F]3F4AP
- **DRUG:** [18F]MK6240
- **DRUG:** [11C]PIB

## Key facts

- **NCT ID:** NCT06999434
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-05
- **Primary completion:** 2030-05-05
- **Final completion:** 2030-05-05
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06999434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06999434, "Exploring the Utility of [18F]3F4AP for Demyelination Imaging". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06999434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*